Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.53 |
| ▸ | PPARA | Q07869 | 14/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001593 | 1.00 | PPARD (0.53) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL2000624 | 0.92 | PPARD (0.56) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL1999385 | 0.92 | PPARD (0.56) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL2000916 | 0.92 | PPARD (0.56) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL12568676 | 0.82 | PPARD (0.60) | PPARDPPARAPPARG | |
| SCHEMBL12568583 | 0.81 | PPARD (0.57) | PPARDPPARAMAPTPPARGKDM4E | |
| SCHEMBL2003846 | 0.78 | ITGB3 (0.38) | PPARDPPARAPPARGKDM4EALDH1A1 | |
| SCHEMBL2000809 | 0.78 | PPARA (0.58) | PPARDPPARAPPARG | |
| SCHEMBL1998548 | 0.77 | PPARG (0.36) | PPARDPPARAPPARG | |
| SCHEMBL12568683 | 0.75 | PPARA (0.45) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARA 243/4885TP53 2568/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARA 243/4885TP53 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.